Non-invasive Helicobacter Pylori Testing Market - By Test Type (Serologic Test, Urea Breath Test, Stool/Fecal Antigen Test), By Method (Laboratory Based Test, Point of Care (POC) Test), By End-Use (Hospital, Diagnostic Labs) & Forecast, 2024 – 2032

Non-invasive Helicobacter Pylori Testing Market - By Test Type (Serologic Test, Urea Breath Test, Stool/Fecal Antigen Test), By Method (Laboratory Based Test, Point of Care (POC) Test), By End-Use (Hospital, Diagnostic Labs) & Forecast, 2024 – 2032

Non-invasive Helicobacter Pylori Testing Market Size

Non-invasive helicobacter pylori testing market size was valued at around USD 273.6 million in 2023 and is estimated to grow at 7.1% CAGR from 2024 to 2032. The rising prevalence of gastric and duodenal illnesses, such as gastric cancer and peptic ulcer disease, is driving the demand for non-invasive Helicobacter Pylori (H. pylori) testing. H. pylori infection is a significant risk factor for these conditions, and non-invasive testing is often used as the first line of treatment for H. pylori infections.

To get key market trends

  Download Free Sample

According to data reported by American Cancer Society, approximately 26,890 new cases of stomach cancer are diagnosed each year in the U.S. including 16,160 cases in men and 10,730 cases in women. Furthermore, non-invasive methods are increasingly being used for the diagnosis of helicobacter pylori infections, particularly in children. High throughput diagnostic systems are being developed for local diagnostic testing, which can provide quick and accurate results.
 

What are the growth opportunities in this market?

 Download Free Sample

Non-invasive helicobacter pylori testing refers to diagnostic methods used to detect the presence of H. pylori bacteria in the gastrointestinal tract without the need for invasive procedures such as endoscopy. These tests are designed to be simple, safe, and relatively comfortable for the patient, as they do not require the insertion of instruments into the body.

Non-invasive Helicobacter Pylori Testing Market Trends

The latest advancements in laboratory serological assay for non-invasive Helicobacter pylori testing include the development of high throughput diagnostic systems for local diagnostic testing. These systems are designed to improve the efficiency and accuracy of helicobacter pylori testing.

• Molecular methods such as real-time PCR assays, are also being used for the detection of H-pylori in stool specimens, with high sensitivity and specificity. These methods can also be used to detect antibiotic resistance, which is important for the effective treatment of H-pylori infection.
• In addition, there have been advancements in the use of point-of-care (POC) tests for the detection of H. pylori infection, such as lateral flow assays and immunochromatographic assays (ICAs), that can provide rapid results and are easy to use in clinical settings. These advancements enable the growing preferences for non-invasive testing approach for diagnosis of H-pylori.

Non-invasive Helicobacter Pylori Testing Market Analysis

Learn more about the key segments shaping this market

 Download Free Sample

Based on test type, the non-invasive H-pylori testing market is categorized into serologic test, urea breath test, and stool/fecal antigen test. The serologic test segment dominates the market with a revenue of around USD 110.7 million in 2023.

• Serologic tests, which analyze blood samples, are non-invasive in nature compared to other diagnostic methods like endoscopy or biopsy. This makes them more convenient and preferable to patients, especially those who may be reluctant to undergo more invasive procedures.
• Moreover, blood tests can be easily administered in various healthcare settings, including clinics, hospitals, and laboratories. This accessibility and convenience contribute to their widespread adoption.

Based on method, the non-invasive helicobacter pylori testing market is categorized into laboratory-based test and point of care (POC) test. The laboratory-based test segment dominates the market with a revenue of around USD 170.2 million in 2023.

• Laboratory-based tests are often considered the gold standard for diagnostic accuracy and reliability. These tests are performed in controlled laboratory settings by trained professionals which helps minimize variability and ensure consistent results, contributing to the segmental growth.
• Moreover, laboratories offer a wide range of tests and panels capable of detecting multiple markers or analytes simultaneously. This comprehensive approach allows healthcare providers to obtain a more complete picture of a patient's health status, aiding in diagnosis, monitoring, and treatment decision-making.

Learn more about the key segments shaping this market

 Download Free Sample

Based on end-use, the non-invasive helicobacter pylori testing market is categorized into hospitals, clinics, diagnostic laboratories, and other end users. The diagnostic labs segment held a majority market share with a revenue of around USD 119.5 million in 2023.

• Rapid advancements in medical technology, including laboratory instrumentation, diagnostic assays, imaging modalities, and molecular diagnostics, have expanded the capabilities of diagnostic laboratories. These technological innovations enable laboratories to offer a diverse array of tests with improved accuracy, sensitivity, and specificity, driving demand for their services.
• Moreover, as the prevalence of chronic and infectious diseases, continues to rise globally, there is a growing demand for diagnostic services. Diagnostic laboratories play a critical role in diagnosing a wide range of diseases and health conditions, thereby supporting timely intervention and treatment.

Looking for region specific data?

 Download Free Sample

North America non-invasive helicobacter pylori testing market accounted for USD 97.7 million in revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.

• A confluence of factors contributes to the demand for non-invasive helicobacter pylori testing, in the region. For instance, favorable reimbursement policies and the region's higher healthcare expenditure empower healthcare providers to invest in innovative diagnostic technologies.
• Moreover, the aging population and increasing prevalence of chronic conditions drive the need for efficient and accurate diagnostic methods.

The U.S. held a dominant position in the North America non-invasive helicobacter pylori testing market, with a revenue of USD 90.2 million in 2023.

• The emphasis on patient safety and comfort during non-invasive diagnostic methods further boosts the H pylori testing volume in the country.
• Increased awareness about the health risks associated with untreated H. pylori infection has led to higher demand for testing among healthcare providers and patients. Individuals are more proactive about screening for H. pylori, especially if they experience symptoms such as abdominal pain, nausea, or indigestion.

Japan non-invasive helicobacter pylori testing market is anticipated to witness substantial growth during 2024-2032.

• Japan's market is poised for substantial growth owing to its aging population and rising prevalence for different gastric conditions.
• With an emphasis on patient safety and comfort, there is a surging demand for advanced diagnostic solutions. Hospitals and care facilities prioritize innovative technologies like non-invasive H. pylori testing to ensure efficient and safe diagnostic processes.

China exhibits a high growth potential in the non-invasive helicobacter pylori testing market.

• The expanding healthcare infrastructure and government initiatives in China aimed at enhancing healthcare quality.
• As healthcare facilities modernize and prioritize patient care, there is an increasing demand for advanced diagnostic procedures such as non-invasive H pylori testing to ensure accurate diagnoses while minimizing patient discomfort and risk.

In Europe, the ongoing research and development efforts, fuels innovation in diagnostic technologies.

• Ongoing advancements in diagnostic technologies have led to the development of more accurate, sensitive, and user-friendly non-invasive H. pylori testing kits. These innovations have enhanced the reliability and accessibility of testing, driving adoption rates among healthcare facilities and patients.
• Non-invasive testing methods, such as urea breath tests and stool antigen tests, offer greater convenience and patient compliance compared to invasive procedures. This leads to higher acceptance rates among patients, particularly those reluctant to undergo endoscopic examinations.

Non-invasive Helicobacter Pylori Testing Market Share

The non-invasive helicobacter pylori testing industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel diagnostic tests with improved efficiency and cost-effectiveness are key market strategies for industry players, driving competition and innovation in the market. This emphasis on innovation aims to address evolving clinical needs and enhance patient outcomes, positioning companies to gain market share and meet the growing demand for advanced non-invasive H pylori testing.

Non-invasive Helicobacter Pylori Testing Companies

Some of the eminent market participants operating in the non-invasive helicobacter pylori testing industry include

• Abbott
• Biohit Oyj
• Bio-Rad Laboratories, Inc.
• Cardinal Health
• certest Biotech srl
• Fisher Scientific
• Gulf Coast Scientific
• Meridian Bioscience Inc.
• Quidel Corporation
• Tri-Med

Non-invasive Helicobacter Pylori Testing Industry News

• In July 2023, Meridian Bioscience received FDA clearance for its latest advancement in H. pylori diagnostic testing solutions Premier HpSA Flex. This development signified a notable step forward in non-invasive diagnostic testing and expanded the company’s market presence in the non-invasive H. pylori testing market.

Non-invasive helicobacter pylori testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments

Click here to Buy Section of this Report

Market, By Test Type

• Serologic test
• Urea breath test     
• Stool/fecal antigen test

By Method

• Laboratory based test       
• Point of care (POC) test                        

By End-user 

• Hospitals      
• Clinics         
• Diagnostic laboratories
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa